Skip to main content

Read more about our corporate brand here.

Search
Search
Reports

Healthcare Industry Trends

2023 Annual Report
Raysa Bousleiman, Josh Pherigo, Jackie Spencer

Key takeaways

Our 13th Healthcare Investments & Exits report examines how fundraising, investment and exit trends are impacting the VC-backed healthcare ecosystem. This edition unlocks new insights through our first-ever analyses around generative AI, spoon-fed deals and the occurrences of down, flat and up rounds.

$19B

Raised by US VC firms for health-focused funds

2023 was the third-best year for healthcare fundraising in the past decade.

42%

Of healthcare deals were spoon-fed

The proportion of deals involving later-stage companies valued at more than $20M raising $15M or less is on the rise.

19

Total number of biopharma IPOs

Biopharma exits are historically low, but the IPO market is showing signs of life.

The data

Our proprietary insights report takes an in-depth look at the key investments and exits trends within biopharma, healthtech, dx/tools and device. New to this year's report is a deep dive on the thriving women's health subsector.

HEALTHCARE VC FUNDRAISING

Fundraising is bright spot for healthcare

Investors are cutting smaller checks, deploying capital more slowly and focusing more on diligence. But total fundraising for new health-focused VC and growth funds is down only 14% from 2022 and remains the third highest total over the past decade.

This year's wave of down and flat rounds of funding have undoubtedly been painful for companies and their shareholders in the short term, but it has also led to a right-sizing of the market, laying the groundwork for a more sustainable future.

Chart depicting US healthcare venture capital fundraising from 2012 to 2023 Note: US Healthcare Venture Capital Fundraising defined as an approximation of healthcare investment dollars to be invested by firms that historically invest in +50% US companies Source: PitchBook and SVB proprietary data
Chart depicting the proportion of spoon-fed deals by sector in 2021 and 2023 Note: A spoon-fed deal is defined as a deal that is $15M or less for later stage company with a pre-money valuation at or above $20M Source: PitchBook and SVB proprietary data
HEALTHCARE INVESTMENTS

Investors keep companies alive with spoon-fed deals

The proportion of spoon-fed deals has increased dramatically for all but one healthcare sector since 2021, as investors increasingly use inside and extension rounds to help companies weather a challenging market.

While biopharma, diagnostics and healthtech all saw a large spike, the percentage of biopharma spoon-fed remains relatively low, likely because the sector is driven more by clinical milestones.

BIOPHARMA EXITS

Late-stage biopharma companies find exits

The total value of biopharma IPOs and disclosed M&A deals remained flat in 2023 — and well below the 2021 peak. But the sector saw 19 IPOs, more than all other healthcare sectors combined.

Public exits in biopharma have been restricted to later-stage companies with robust clinical milestones. Most biopharma IPOs were Phase II or beyond, and none were pre-clinical.

Chart depicting biopharma private M&A deals and IPOs from 2019 through 2026 Source: PitchBook and SVB analysis.

Read the full Healthcare Investments & Exits Report

Explore our insights and commentary on the 2023 investment landscape.

More about the authors

Raysa Bousleiman

Raysa Bousleiman

Josh Pherigo
Market Insights

Josh Pherigo

Principal Researcher

Jackie Spencer

Jackie Spencer


Explore other First Citizens Innovation Banking Reports

The Future of Healthtech 2026 Reports
Read Report Report

The Future of Healthtech 2026

Nov 09, 2026

Megan Scheffel, Adam Tweedy, Dennis He, Matt Donne, Alex Lennox-Miller, Urbashee Paul, Josh Pherigo

The Future of Fintech 2026 Reports
Read Report Report

The Future of Fintech 2026

Oct 13, 2026

Nick Christian, Brian Foley, Julie Wagne, Sophie McNaught, Josh Pherigo, Eli Oftedal, Andrew Pardo

The Future of Climate Tech Reports
Read Report Report

The Future of Climate Tech

Apr 15, 2026

Jordan Kanis, Eli Oftedal, Josh Pherigo, Andrew Pardo


The views expressed in this report are solely those of the authors and do not necessarily reflect the views of First Citizens Innovation Banking or Counterpart.

All non-SVB named companies listed throughout this document are independent third parties and are not affiliated with Silicon Valley Bank, a division of First-Citizens Bank & Trust Company.

This material, including without limitation to the statistical information herein, is provided for informational purposes only. The material is based in part on information from third-party sources that we believe to be reliable, but which has not been independently verified by us, and, as such, we do not represent the information is accurate or complete. The information should not be viewed as tax, accounting, investment, legal or other advice, nor is it to be relied on in making an investment or other decision. You should obtain relevant and specific professional advice before making any investment decision. Nothing relating to the material should be construed as a solicitation, offer or recommendation to acquire or dispose of any investment, or to engage in any other transaction.

Back to top
You are now leaving First Citizens Innovation Banking

You will be directed to a different website or mobile app that has its own terms of use, visitor agreement, security and privacy policies. First Citizens Innovation Banking is not responsible for (and does not provide) any products, services or content at the third party site or app, except for the products and services that carry the First Citizens Innovation Banking name.